Articles

Retatrutide is a triple incretin agonist that produced 24.2 percent mean body-weight loss at 48 weeks in Phase 2, numerically exceeding both semaglutide and tirzepatide. No controlled trial has matched calorie intake and exercise exposure across all three agents. The fat-mass-specific advantage therefore remains mechanistically inferred rather than directly demonstrated in a head-to-head design.

A 2026 Phase 4 trial actively recruiting virally suppressed adults with HIV tests whether tirzepatide's dual GIP/GLP-1 co-agonism can simultaneously reduce epigenetic aging pace and restore metabolic markers — and whether those changes correlate with visceral fat and lean mass shifts. HIV-associated visceral adiposity and chronic immune activation are independent epigenetic clock accelerants; tirzepatide targets both axes simultaneously.

Yes — resistance training fundamentally alters lean-mass outcomes during GLP-1 therapy. Without it, semaglutide users lose 25–40% of total weight as lean tissue. Controlled exercise interventions reduce that fraction to roughly 10–15% by activating a RAGULATOR-independent mTORC1 pathway that operates even under deep caloric deficits, while protein intake above 1.6 g/kg/day adds a mechanistically distinct, additive protective signal.

A 2026 narrative review in Pharmaceuticals (MDPI) and ASCO 2026 real-world data reframe semaglutide's oncogenic and cardiotoxicity profile in quantitative terms. Key figures include a 21% preferential visceral fat reduction, a weight-independent 20% MACE reduction, and 38 to 50% lower metastatic progression rates across four obesity-linked cancers. These numbers shift the risk-benefit calculus decisively toward net benefit for body-composition practitioners.

The 2026 Springer review in Endocrine (doi:10.1007/s12020-026-04686-5) identifies tirzepatide's cardio-renal axis as a mechanistically distinct integration layer. Dual GIP/GLP-1 receptor co-agonism reduces left ventricular mass, lowers NT-proBNP, cuts composite cardiorenal events versus dulaglutide, and slows eGFR decline — outcomes that reframe tirzepatide's value for metabolically compromised performance users carrying cardiovascular risk.

Dietary geroprotective peptides modulate Nrf2, IIS, and mTOR through three converging structural rules: molecular weight below 1 kDa for intestinal permeation, hydrophobic or aromatic C-terminal residues for Keap1 displacement and receptor docking, and ETGE-like sequence motifs that mimic endogenous signaling ligands. These features are now mappable by AI-driven structure-activity pipelines, directly linking food-protein sequence to conserved longevity network outputs.

A 2026 review in Expert Review of Clinical Pharmacology (Tandfonline) applies a systems medicine framework to semaglutide, integrating proteomic and metabolomic datasets with major RCT outcomes. The synthesis identifies three converging pathway clusters — inflammatory signalling, lipid remodelling, and extracellular matrix regulation — that collectively explain why semaglutide's metabolic effects exceed what GLP-1 receptor agonism alone predicts.

BRP (BRINP2-related peptide) is a computationally identified 12-amino-acid peptide that suppresses appetite and reduces fat mass in rodents and minipigs via a hypothalamic cAMP–PKA–CREB–FOS signaling axis entirely distinct from incretin pathways. Unlike GLP-1 receptor agonists, BRP produced no conditioned taste aversion or delayed gastric emptying in preclinical models, while generating a comparable or stronger hypothalamic Fos response than GLP-1 itself.

The 2026 Springer review establishes tirzepatide as a genuine multi-organ metabolic integrator: its dual GIP/GLP-1 receptor co-agonism simultaneously reshapes adipose lipolysis, hepatic lipid flux, skeletal muscle glucose uptake, and pancreatic beta-cell function. The net body composition result is 22 to 25 percent total weight loss with approximately 75 percent attributable to fat mass, outperforming semaglutide monotherapy in comparative analyses.

Incretin mimetics suppress appetite so aggressively that absolute protein intake collapses well below the minimum threshold needed to sustain muscle protein synthesis. Deliberate high-protein targeting restores leucine-triggered mTORC1 signalling. Incretin-stimulated insulin simultaneously amplifies postprandial amino acid uptake. Together these inputs form a mechanistically complementary pairing that 2024–2025 trial data increasingly supports.

A 2026 narrative review in Pharmaceuticals (MDPI, DOI: 10.3390/ph19020297) maps semaglutide's pleiotropic effects onto two domains relevant to performance practitioners: oncogenic signalling risk and mitigation of chemotherapy-driven cardiotoxicity. The net oncogenic signal is confounded by obesity itself; the cardiotoxicity mitigation data are preclinical but mechanistically precise. Both domains alter risk stratification for specific user profiles.

FDA scientists' pre-meeting briefing documents for the July 23–24, 2026 PCAC hearing recommended against adding TB-500, BPC-157, and MOTS-C to the 503A Bulk Drug Substances List. The core finding: zero human clinical studies support the proposed uses for TB-500 and MOTS-C, while BPC-157's preclinical data cannot substitute for absent human efficacy evidence under the 503A standard.